Silence TherapeuticsSLN +7.20%45 PS Ratio is 599.44 as of Jun. 29, 2026, which is 2519% above its 10-year median of 22.89. GuruFocus rates SLN with a GF Score™ of 45/100 and a GF Value™ of $0.23 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 935 Biotechnology companies, Silence Therapeutics ranks worse than 92.41% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Silence Therapeutics's share price is $10.79.
Silence Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.02. Hence, Silence Therapeutics's PS Ratio for today is 599.44.
The historical rank and industry rank for Silence Therapeutics's PS Ratio or its related term are showing as below:
SLN'
s PS Ratio Range Over the Past 10 Years
Min: 1.74 Med: 22.89 Max: 500
Current: 393.06
During the past 13 years, Silence Therapeutics's highest PS Ratio was 500.00. The lowest was 1.74. And the median was 22.89.
SLN's PS Ratio is ranked worse than 92.41% of 935
companies
in the Biotechnology industry
Industry Median: 9.29
vs SLN: 393.06
Silence Therapeutics PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Silence Therapeutics was -96.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -73.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -32.70% per year.
During the past 13 years, Silence Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 282.60% per year. The lowest was -81.70% per year. And the median was -19.80% per year.
Back to Basics: PS Ratio
Silence Therapeutics (NAS:SLN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Silence Therapeutics PS Ratio Related Terms
Silence Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Silence Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Silence Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silence Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Silence Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Silence Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Silence Therapeutics's Share Price of today is $10.79. Silence Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Silence Therapeutics (SLN) has a PS Ratio of 599.44 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Silence Therapeutics and its competitors. This is 2519% above median its historical median of 22.89. Over the past decade, Silence Therapeutics' PS Ratio has ranged from 1.74 to 500.00. According to the industry distribution chart, Silence Therapeutics ranks #864 out of 935 companies in the Biotechnology industry, placing it in the top 92.4%.
Is Silence Therapeutics' PS Ratio too high?
Silence Therapeutics' current PS Ratio of 599.44 is 2519% above median its 10-year median of 22.89. Over the past 10 years, this metric has ranged from a low of 1.74 to a high of 500.00. The Biotechnology industry median PS Ratio is 9.29. Silence Therapeutics' value of 599.44 is 6352.5% above this industry median. Based on the distribution chart, Silence Therapeutics ranks #864 out of 935 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Silence Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' PS Ratio compare to IMRX and VRXA?
According to the Biotechnology industry distribution chart, Silence Therapeutics ranks #864 out of 935 companies for PS Ratio. This places Silence Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.29. Silence Therapeutics' value of 599.44 is 6352.5% above this benchmark. Historically, Silence Therapeutics' own PS Ratio has ranged from 1.74 to 500.00 over the past decade. While the company's 10-year median is 22.89 vs. the industry median of 9.29, Silence Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.29, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Silence Therapeutics's current PS Ratio of 599.44 is 6352.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Silence Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Silence Therapeutics's current PS Ratio is 599.44, which is 2519% above median its own 10-year median of 22.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.23, compared to a current price of $10.79 — trading 4591.3% above its estimated fair value. The current PS Ratio is 599.44, which is 2519% above median its 10-year median of 22.89 and 6352.5% above the Biotechnology industry median of 9.29. Silence Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current PS Ratio is 599.44 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Silence Therapeutics (SLN) Overvalued in 2026?
Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued.
The current stock price of $10.79 is trading 4591.3% above its estimated GF Value™ of $0.23.
GuruFocus considers Silence Therapeutics to be Significantly Overvalued.
Key valuation signals for SLN:
PS Ratio: 599.44 (2519% above median its 10-year median of 22.89)
GF Value™: $0.23 vs. price of $10.79 (4591.3% above fair value)
Industry Position: 6352.5% above the Biotechnology median (#864 of 935)
No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
45GF Score
Get the complete analysis for SLN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLN has been successfully added to your 
